Using Kidney Genetics to Make Clinical Trials More Precise
Broad kidney disease labels often hide important biological differences, which can mess up clinical trials. In a recent podcast, Dr. Ronen Schneider from Natera explains how genetic testing combined with real-world health data helps drug developers find the right patient groups.
Original image temporarily unavailable
Background
Traditional labels for chronic kidney disease are often too broad, lumping together patients with very different underlying biology. This hidden diversity can cause clinical trials to fail or produce misleading results because the treatment is not being tested on the right people.
Details and Impact
Dr. Ronen Schneider discusses how tools like RenasightIQ combine genetic results with clinical histories, lab work, and insurance claims from over 300,000 patients. By evaluating genotypes as trial variables, drug developers can better understand natural disease progression, choose smarter endpoints, and improve patient recruitment. This approach helps teams spot hidden variations in past studies and stress-test future strategies using real-world data.
View selection rationale
Importance 14/100
About this brief
- Content type
- Research summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.